0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Antifibrotic Drug Market Research Report 2024
Published Date: August 2024
|
Report Code: QYRE-Auto-29J17746
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Antifibrotic Drug Market Research Report 2024
BUY CHAPTERS

Global Antifibrotic Drug Market Research Report 2024

Code: QYRE-Auto-29J17746
Report
August 2024
Pages:98
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Antifibrotic Drug Market

Antifibrotic drugs are medications specifically designed to inhibit or slow down the process of fibrosis.The two main antifibrotic agents used for IPF are pirfenidone and nintedanib.Pirfenidone works by inhibiting processes involved in fibrosis,including reducing the production of pro-inflammatory cytokines and inhibiting fibroblast proliferation and collagen synthesis.Nintedanib,on the other hand,targets multiple tyrosine kinases that are implicated in pathways leading to fibrosis,thereby interfering with the progression of lung scarring.
The global Antifibrotic Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Antifibrotic Drug is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Antifibrotic Drug is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Antifibrotic Drug include Boehringer Ingelheim, Roche, Accord Healthcare, Amneal Pharmaceuticals, Sandoz, Teva, ScieGen Pharmaceuticals, Apotex, Gyre Pharmaceuticals, Kawin, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Antifibrotic Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antifibrotic Drug.
The Antifibrotic Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Antifibrotic Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antifibrotic Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Antifibrotic Drug Market Report

Report Metric Details
Report Name Antifibrotic Drug Market
Segment by Type
  • Nintedanib
  • Pirfenidone
Segment by Application
  • Hospital and Clinic
  • Retail Pharmacies
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Boehringer Ingelheim, Roche, Accord Healthcare, Amneal Pharmaceuticals, Sandoz, Teva, ScieGen Pharmaceuticals, Apotex, Gyre Pharmaceuticals, Kawin, Beacon Pharma, Eskayef Pharmaceuticals, CSPC Pharmaceutical Group, Qilu Pharmaceutical, Kelun Pharmaceutical, PuraCap
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Antifibrotic Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Antifibrotic Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Antifibrotic Drug Market report?

Ans: The main players in the Antifibrotic Drug Market are Boehringer Ingelheim, Roche, Accord Healthcare, Amneal Pharmaceuticals, Sandoz, Teva, ScieGen Pharmaceuticals, Apotex, Gyre Pharmaceuticals, Kawin, Beacon Pharma, Eskayef Pharmaceuticals, CSPC Pharmaceutical Group, Qilu Pharmaceutical, Kelun Pharmaceutical, PuraCap

What are the Application segmentation covered in the Antifibrotic Drug Market report?

Ans: The Applications covered in the Antifibrotic Drug Market report are Hospital and Clinic, Retail Pharmacies, Other

What are the Type segmentation covered in the Antifibrotic Drug Market report?

Ans: The Types covered in the Antifibrotic Drug Market report are Nintedanib, Pirfenidone

Recommended Reports

Pulmonary Disease Drugs

Fibrosis Related Drugs

Anti-Fibrotic & VEGF Drugs

1 Antifibrotic Drug Market Overview
1.1 Product Definition
1.2 Antifibrotic Drug by Type
1.2.1 Global Antifibrotic Drug Market Value Comparison by Type (2024-2030)
1.2.2 Nintedanib
1.2.3 Pirfenidone
1.3 Antifibrotic Drug by Application
1.3.1 Global Antifibrotic Drug Market Value by Application (2024-2030)
1.3.2 Hospital and Clinic
1.3.3 Retail Pharmacies
1.3.4 Other
1.4 Global Antifibrotic Drug Market Size Estimates and Forecasts
1.4.1 Global Antifibrotic Drug Revenue 2019-2030
1.4.2 Global Antifibrotic Drug Sales 2019-2030
1.4.3 Global Antifibrotic Drug Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Antifibrotic Drug Market Competition by Manufacturers
2.1 Global Antifibrotic Drug Sales Market Share by Manufacturers (2019-2024)
2.2 Global Antifibrotic Drug Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Antifibrotic Drug Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of Antifibrotic Drug, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Antifibrotic Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Antifibrotic Drug, Product Type & Application
2.7 Global Key Manufacturers of Antifibrotic Drug, Date of Enter into This Industry
2.8 Global Antifibrotic Drug Market Competitive Situation and Trends
2.8.1 Global Antifibrotic Drug Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Antifibrotic Drug Players Market Share by Revenue
2.8.3 Global Antifibrotic Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Antifibrotic Drug Market Scenario by Region
3.1 Global Antifibrotic Drug Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Antifibrotic Drug Sales by Region: 2019-2030
3.2.1 Global Antifibrotic Drug Sales by Region: 2019-2024
3.2.2 Global Antifibrotic Drug Sales by Region: 2025-2030
3.3 Global Antifibrotic Drug Revenue by Region: 2019-2030
3.3.1 Global Antifibrotic Drug Revenue by Region: 2019-2024
3.3.2 Global Antifibrotic Drug Revenue by Region: 2025-2030
3.4 North America Antifibrotic Drug Market Facts & Figures by Country
3.4.1 North America Antifibrotic Drug Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Antifibrotic Drug Sales by Country (2019-2030)
3.4.3 North America Antifibrotic Drug Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Antifibrotic Drug Market Facts & Figures by Country
3.5.1 Europe Antifibrotic Drug Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Antifibrotic Drug Sales by Country (2019-2030)
3.5.3 Europe Antifibrotic Drug Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Antifibrotic Drug Market Facts & Figures by Region
3.6.1 Asia Pacific Antifibrotic Drug Market Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Antifibrotic Drug Sales by Region (2019-2030)
3.6.3 Asia Pacific Antifibrotic Drug Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Antifibrotic Drug Market Facts & Figures by Country
3.7.1 Latin America Antifibrotic Drug Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Antifibrotic Drug Sales by Country (2019-2030)
3.7.3 Latin America Antifibrotic Drug Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Antifibrotic Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Antifibrotic Drug Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Antifibrotic Drug Sales by Country (2019-2030)
3.8.3 Middle East and Africa Antifibrotic Drug Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Antifibrotic Drug Sales by Type (2019-2030)
4.1.1 Global Antifibrotic Drug Sales by Type (2019-2024)
4.1.2 Global Antifibrotic Drug Sales by Type (2025-2030)
4.1.3 Global Antifibrotic Drug Sales Market Share by Type (2019-2030)
4.2 Global Antifibrotic Drug Revenue by Type (2019-2030)
4.2.1 Global Antifibrotic Drug Revenue by Type (2019-2024)
4.2.2 Global Antifibrotic Drug Revenue by Type (2025-2030)
4.2.3 Global Antifibrotic Drug Revenue Market Share by Type (2019-2030)
4.3 Global Antifibrotic Drug Price by Type (2019-2030)
5 Segment by Application
5.1 Global Antifibrotic Drug Sales by Application (2019-2030)
5.1.1 Global Antifibrotic Drug Sales by Application (2019-2024)
5.1.2 Global Antifibrotic Drug Sales by Application (2025-2030)
5.1.3 Global Antifibrotic Drug Sales Market Share by Application (2019-2030)
5.2 Global Antifibrotic Drug Revenue by Application (2019-2030)
5.2.1 Global Antifibrotic Drug Revenue by Application (2019-2024)
5.2.2 Global Antifibrotic Drug Revenue by Application (2025-2030)
5.2.3 Global Antifibrotic Drug Revenue Market Share by Application (2019-2030)
5.3 Global Antifibrotic Drug Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Boehringer Ingelheim
6.1.1 Boehringer Ingelheim Company Information
6.1.2 Boehringer Ingelheim Description and Business Overview
6.1.3 Boehringer Ingelheim Antifibrotic Drug Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Boehringer Ingelheim Antifibrotic Drug Product Portfolio
6.1.5 Boehringer Ingelheim Recent Developments/Updates
6.2 Roche
6.2.1 Roche Company Information
6.2.2 Roche Description and Business Overview
6.2.3 Roche Antifibrotic Drug Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Roche Antifibrotic Drug Product Portfolio
6.2.5 Roche Recent Developments/Updates
6.3 Accord Healthcare
6.3.1 Accord Healthcare Company Information
6.3.2 Accord Healthcare Description and Business Overview
6.3.3 Accord Healthcare Antifibrotic Drug Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Accord Healthcare Antifibrotic Drug Product Portfolio
6.3.5 Accord Healthcare Recent Developments/Updates
6.4 Amneal Pharmaceuticals
6.4.1 Amneal Pharmaceuticals Company Information
6.4.2 Amneal Pharmaceuticals Description and Business Overview
6.4.3 Amneal Pharmaceuticals Antifibrotic Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Amneal Pharmaceuticals Antifibrotic Drug Product Portfolio
6.4.5 Amneal Pharmaceuticals Recent Developments/Updates
6.5 Sandoz
6.5.1 Sandoz Company Information
6.5.2 Sandoz Description and Business Overview
6.5.3 Sandoz Antifibrotic Drug Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Sandoz Antifibrotic Drug Product Portfolio
6.5.5 Sandoz Recent Developments/Updates
6.6 Teva
6.6.1 Teva Company Information
6.6.2 Teva Description and Business Overview
6.6.3 Teva Antifibrotic Drug Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Teva Antifibrotic Drug Product Portfolio
6.6.5 Teva Recent Developments/Updates
6.7 ScieGen Pharmaceuticals
6.7.1 ScieGen Pharmaceuticals Company Information
6.7.2 ScieGen Pharmaceuticals Description and Business Overview
6.7.3 ScieGen Pharmaceuticals Antifibrotic Drug Sales, Revenue and Gross Margin (2019-2024)
6.7.4 ScieGen Pharmaceuticals Antifibrotic Drug Product Portfolio
6.7.5 ScieGen Pharmaceuticals Recent Developments/Updates
6.8 Apotex
6.8.1 Apotex Company Information
6.8.2 Apotex Description and Business Overview
6.8.3 Apotex Antifibrotic Drug Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Apotex Antifibrotic Drug Product Portfolio
6.8.5 Apotex Recent Developments/Updates
6.9 Gyre Pharmaceuticals
6.9.1 Gyre Pharmaceuticals Company Information
6.9.2 Gyre Pharmaceuticals Description and Business Overview
6.9.3 Gyre Pharmaceuticals Antifibrotic Drug Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Gyre Pharmaceuticals Antifibrotic Drug Product Portfolio
6.9.5 Gyre Pharmaceuticals Recent Developments/Updates
6.10 Kawin
6.10.1 Kawin Company Information
6.10.2 Kawin Description and Business Overview
6.10.3 Kawin Antifibrotic Drug Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Kawin Antifibrotic Drug Product Portfolio
6.10.5 Kawin Recent Developments/Updates
6.11 Beacon Pharma
6.11.1 Beacon Pharma Company Information
6.11.2 Beacon Pharma Description and Business Overview
6.11.3 Beacon Pharma Antifibrotic Drug Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Beacon Pharma Antifibrotic Drug Product Portfolio
6.11.5 Beacon Pharma Recent Developments/Updates
6.12 Eskayef Pharmaceuticals
6.12.1 Eskayef Pharmaceuticals Company Information
6.12.2 Eskayef Pharmaceuticals Description and Business Overview
6.12.3 Eskayef Pharmaceuticals Antifibrotic Drug Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Eskayef Pharmaceuticals Antifibrotic Drug Product Portfolio
6.12.5 Eskayef Pharmaceuticals Recent Developments/Updates
6.13 CSPC Pharmaceutical Group
6.13.1 CSPC Pharmaceutical Group Company Information
6.13.2 CSPC Pharmaceutical Group Description and Business Overview
6.13.3 CSPC Pharmaceutical Group Antifibrotic Drug Sales, Revenue and Gross Margin (2019-2024)
6.13.4 CSPC Pharmaceutical Group Antifibrotic Drug Product Portfolio
6.13.5 CSPC Pharmaceutical Group Recent Developments/Updates
6.14 Qilu Pharmaceutical
6.14.1 Qilu Pharmaceutical Company Information
6.14.2 Qilu Pharmaceutical Description and Business Overview
6.14.3 Qilu Pharmaceutical Antifibrotic Drug Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Qilu Pharmaceutical Antifibrotic Drug Product Portfolio
6.14.5 Qilu Pharmaceutical Recent Developments/Updates
6.15 Kelun Pharmaceutical
6.15.1 Kelun Pharmaceutical Company Information
6.15.2 Kelun Pharmaceutical Description and Business Overview
6.15.3 Kelun Pharmaceutical Antifibrotic Drug Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Kelun Pharmaceutical Antifibrotic Drug Product Portfolio
6.15.5 Kelun Pharmaceutical Recent Developments/Updates
6.16 PuraCap
6.16.1 PuraCap Company Information
6.16.2 PuraCap Description and Business Overview
6.16.3 PuraCap Antifibrotic Drug Sales, Revenue and Gross Margin (2019-2024)
6.16.4 PuraCap Antifibrotic Drug Product Portfolio
6.16.5 PuraCap Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Antifibrotic Drug Industry Chain Analysis
7.2 Antifibrotic Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Antifibrotic Drug Production Mode & Process
7.4 Antifibrotic Drug Sales and Marketing
7.4.1 Antifibrotic Drug Sales Channels
7.4.2 Antifibrotic Drug Distributors
7.5 Antifibrotic Drug Customers
8 Antifibrotic Drug Market Dynamics
8.1 Antifibrotic Drug Industry Trends
8.2 Antifibrotic Drug Market Drivers
8.3 Antifibrotic Drug Market Challenges
8.4 Antifibrotic Drug Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Antifibrotic Drug Market Value Comparison by Type (2024-2030) & (US$ Million)
 Table 2. Global Antifibrotic Drug Market Value by Application (2024-2030) & (US$ Million)
 Table 3. Global Antifibrotic Drug Market Competitive Situation by Manufacturers in 2023
 Table 4. Global Antifibrotic Drug Sales (K Units) of Key Manufacturers (2019-2024)
 Table 5. Global Antifibrotic Drug Sales Market Share by Manufacturers (2019-2024)
 Table 6. Global Antifibrotic Drug Revenue (US$ Million) by Manufacturers (2019-2024)
 Table 7. Global Antifibrotic Drug Revenue Share by Manufacturers (2019-2024)
 Table 8. Global Market Antifibrotic Drug Average Price (US$/Unit) of Key Manufacturers (2019-2024)
 Table 9. Global Key Players of Antifibrotic Drug, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Antifibrotic Drug, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Antifibrotic Drug, Product Type & Application
 Table 12. Global Key Manufacturers of Antifibrotic Drug, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Antifibrotic Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antifibrotic Drug as of 2023)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Antifibrotic Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Table 17. Global Antifibrotic Drug Sales by Region (2019-2024) & (K Units)
 Table 18. Global Antifibrotic Drug Sales Market Share by Region (2019-2024)
 Table 19. Global Antifibrotic Drug Sales by Region (2025-2030) & (K Units)
 Table 20. Global Antifibrotic Drug Sales Market Share by Region (2025-2030)
 Table 21. Global Antifibrotic Drug Revenue by Region (2019-2024) & (US$ Million)
 Table 22. Global Antifibrotic Drug Revenue Market Share by Region (2019-2024)
 Table 23. Global Antifibrotic Drug Revenue by Region (2025-2030) & (US$ Million)
 Table 24. Global Antifibrotic Drug Revenue Market Share by Region (2025-2030)
 Table 25. North America Antifibrotic Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 26. North America Antifibrotic Drug Sales by Country (2019-2024) & (K Units)
 Table 27. North America Antifibrotic Drug Sales by Country (2025-2030) & (K Units)
 Table 28. North America Antifibrotic Drug Revenue by Country (2019-2024) & (US$ Million)
 Table 29. North America Antifibrotic Drug Revenue by Country (2025-2030) & (US$ Million)
 Table 30. Europe Antifibrotic Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 31. Europe Antifibrotic Drug Sales by Country (2019-2024) & (K Units)
 Table 32. Europe Antifibrotic Drug Sales by Country (2025-2030) & (K Units)
 Table 33. Europe Antifibrotic Drug Revenue by Country (2019-2024) & (US$ Million)
 Table 34. Europe Antifibrotic Drug Revenue by Country (2025-2030) & (US$ Million)
 Table 35. Asia Pacific Antifibrotic Drug Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
 Table 36. Asia Pacific Antifibrotic Drug Sales by Region (2019-2024) & (K Units)
 Table 37. Asia Pacific Antifibrotic Drug Sales by Region (2025-2030) & (K Units)
 Table 38. Asia Pacific Antifibrotic Drug Revenue by Region (2019-2024) & (US$ Million)
 Table 39. Asia Pacific Antifibrotic Drug Revenue by Region (2025-2030) & (US$ Million)
 Table 40. Latin America Antifibrotic Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 41. Latin America Antifibrotic Drug Sales by Country (2019-2024) & (K Units)
 Table 42. Latin America Antifibrotic Drug Sales by Country (2025-2030) & (K Units)
 Table 43. Latin America Antifibrotic Drug Revenue by Country (2019-2024) & (US$ Million)
 Table 44. Latin America Antifibrotic Drug Revenue Market Share by Country (2019-2024)
 Table 45. Middle East and Africa Antifibrotic Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 46. Middle East and Africa Antifibrotic Drug Sales by Country (2019-2024) & (K Units)
 Table 47. Middle East and Africa Antifibrotic Drug Sales by Country (2025-2030) & (K Units)
 Table 48. Middle East and Africa Antifibrotic Drug Revenue by Country (2019-2024) & (US$ Million)
 Table 49. Middle East and Africa Antifibrotic Drug Revenue by Country (2025-2030) & (US$ Million)
 Table 50. Global Antifibrotic Drug Sales (K Units) by Type (2019-2024)
 Table 51. Global Antifibrotic Drug Sales (K Units) by Type (2025-2030)
 Table 52. Global Antifibrotic Drug Sales Market Share by Type (2019-2024)
 Table 53. Global Antifibrotic Drug Sales Market Share by Type (2025-2030)
 Table 54. Global Antifibrotic Drug Revenue (US$ Million) by Type (2019-2024)
 Table 55. Global Antifibrotic Drug Revenue (US$ Million) by Type (2025-2030)
 Table 56. Global Antifibrotic Drug Revenue Market Share by Type (2019-2024)
 Table 57. Global Antifibrotic Drug Revenue Market Share by Type (2025-2030)
 Table 58. Global Antifibrotic Drug Price (US$/Unit) by Type (2019-2024)
 Table 59. Global Antifibrotic Drug Price (US$/Unit) by Type (2025-2030)
 Table 60. Global Antifibrotic Drug Sales (K Units) by Application (2019-2024)
 Table 61. Global Antifibrotic Drug Sales (K Units) by Application (2025-2030)
 Table 62. Global Antifibrotic Drug Sales Market Share by Application (2019-2024)
 Table 63. Global Antifibrotic Drug Sales Market Share by Application (2025-2030)
 Table 64. Global Antifibrotic Drug Revenue (US$ Million) by Application (2019-2024)
 Table 65. Global Antifibrotic Drug Revenue (US$ Million) by Application (2025-2030)
 Table 66. Global Antifibrotic Drug Revenue Market Share by Application (2019-2024)
 Table 67. Global Antifibrotic Drug Revenue Market Share by Application (2025-2030)
 Table 68. Global Antifibrotic Drug Price (US$/Unit) by Application (2019-2024)
 Table 69. Global Antifibrotic Drug Price (US$/Unit) by Application (2025-2030)
 Table 70. Boehringer Ingelheim Company Information
 Table 71. Boehringer Ingelheim Description and Business Overview
 Table 72. Boehringer Ingelheim Antifibrotic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 73. Boehringer Ingelheim Antifibrotic Drug Product
 Table 74. Boehringer Ingelheim Recent Developments/Updates
 Table 75. Roche Company Information
 Table 76. Roche Description and Business Overview
 Table 77. Roche Antifibrotic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 78. Roche Antifibrotic Drug Product
 Table 79. Roche Recent Developments/Updates
 Table 80. Accord Healthcare Company Information
 Table 81. Accord Healthcare Description and Business Overview
 Table 82. Accord Healthcare Antifibrotic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 83. Accord Healthcare Antifibrotic Drug Product
 Table 84. Accord Healthcare Recent Developments/Updates
 Table 85. Amneal Pharmaceuticals Company Information
 Table 86. Amneal Pharmaceuticals Description and Business Overview
 Table 87. Amneal Pharmaceuticals Antifibrotic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 88. Amneal Pharmaceuticals Antifibrotic Drug Product
 Table 89. Amneal Pharmaceuticals Recent Developments/Updates
 Table 90. Sandoz Company Information
 Table 91. Sandoz Description and Business Overview
 Table 92. Sandoz Antifibrotic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 93. Sandoz Antifibrotic Drug Product
 Table 94. Sandoz Recent Developments/Updates
 Table 95. Teva Company Information
 Table 96. Teva Description and Business Overview
 Table 97. Teva Antifibrotic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 98. Teva Antifibrotic Drug Product
 Table 99. Teva Recent Developments/Updates
 Table 100. ScieGen Pharmaceuticals Company Information
 Table 101. ScieGen Pharmaceuticals Description and Business Overview
 Table 102. ScieGen Pharmaceuticals Antifibrotic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 103. ScieGen Pharmaceuticals Antifibrotic Drug Product
 Table 104. ScieGen Pharmaceuticals Recent Developments/Updates
 Table 105. Apotex Company Information
 Table 106. Apotex Description and Business Overview
 Table 107. Apotex Antifibrotic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 108. Apotex Antifibrotic Drug Product
 Table 109. Apotex Recent Developments/Updates
 Table 110. Gyre Pharmaceuticals Company Information
 Table 111. Gyre Pharmaceuticals Description and Business Overview
 Table 112. Gyre Pharmaceuticals Antifibrotic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 113. Gyre Pharmaceuticals Antifibrotic Drug Product
 Table 114. Gyre Pharmaceuticals Recent Developments/Updates
 Table 115. Kawin Company Information
 Table 116. Kawin Description and Business Overview
 Table 117. Kawin Antifibrotic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 118. Kawin Antifibrotic Drug Product
 Table 119. Kawin Recent Developments/Updates
 Table 120. Beacon Pharma Company Information
 Table 121. Beacon Pharma Description and Business Overview
 Table 122. Beacon Pharma Antifibrotic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 123. Beacon Pharma Antifibrotic Drug Product
 Table 124. Beacon Pharma Recent Developments/Updates
 Table 125. Eskayef Pharmaceuticals Company Information
 Table 126. Eskayef Pharmaceuticals Description and Business Overview
 Table 127. Eskayef Pharmaceuticals Antifibrotic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 128. Eskayef Pharmaceuticals Antifibrotic Drug Product
 Table 129. Eskayef Pharmaceuticals Recent Developments/Updates
 Table 130. CSPC Pharmaceutical Group Company Information
 Table 131. CSPC Pharmaceutical Group Description and Business Overview
 Table 132. CSPC Pharmaceutical Group Antifibrotic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 133. CSPC Pharmaceutical Group Antifibrotic Drug Product
 Table 134. CSPC Pharmaceutical Group Recent Developments/Updates
 Table 135. Qilu Pharmaceutical Company Information
 Table 136. Qilu Pharmaceutical Description and Business Overview
 Table 137. Qilu Pharmaceutical Antifibrotic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 138. Qilu Pharmaceutical Antifibrotic Drug Product
 Table 139. Qilu Pharmaceutical Recent Developments/Updates
 Table 140. Kelun Pharmaceutical Company Information
 Table 141. Kelun Pharmaceutical Description and Business Overview
 Table 142. Kelun Pharmaceutical Antifibrotic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 143. Kelun Pharmaceutical Antifibrotic Drug Product
 Table 144. Kelun Pharmaceutical Recent Developments/Updates
 Table 145. PuraCap Company Information
 Table 146. PuraCap Description and Business Overview
 Table 147. PuraCap Antifibrotic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 148. PuraCap Antifibrotic Drug Product
 Table 149. PuraCap Recent Developments/Updates
 Table 150. Key Raw Materials Lists
 Table 151. Raw Materials Key Suppliers Lists
 Table 152. Antifibrotic Drug Distributors List
 Table 153. Antifibrotic Drug Customers List
 Table 154. Antifibrotic Drug Market Trends
 Table 155. Antifibrotic Drug Market Drivers
 Table 156. Antifibrotic Drug Market Challenges
 Table 157. Antifibrotic Drug Market Restraints
 Table 158. Research Programs/Design for This Report
 Table 159. Key Data Information from Secondary Sources
 Table 160. Key Data Information from Primary Sources
 Table 161. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Antifibrotic Drug
 Figure 2. Global Antifibrotic Drug Market Value Comparison by Type (2024-2030) & (US$ Million)
 Figure 3. Global Antifibrotic Drug Market Share by Type: 2023 & 2030
 Figure 4. Nintedanib Product Picture
 Figure 5. Pirfenidone Product Picture
 Figure 6. Global Antifibrotic Drug Market Value by Application (2024-2030) & (US$ Million)
 Figure 7. Global Antifibrotic Drug Market Share by Application: 2023 & 2030
 Figure 8. Hospital and Clinic
 Figure 9. Retail Pharmacies
 Figure 10. Other
 Figure 11. Global Antifibrotic Drug Revenue, (US$ Million), 2019 VS 2023 VS 2030
 Figure 12. Global Antifibrotic Drug Market Size (2019-2030) & (US$ Million)
 Figure 13. Global Antifibrotic Drug Sales (2019-2030) & (K Units)
 Figure 14. Global Antifibrotic Drug Average Price (US$/Unit) & (2019-2030)
 Figure 15. Antifibrotic Drug Report Years Considered
 Figure 16. Antifibrotic Drug Sales Share by Manufacturers in 2023
 Figure 17. Global Antifibrotic Drug Revenue Share by Manufacturers in 2023
 Figure 18. Global 5 and 10 Largest Antifibrotic Drug Players: Market Share by Revenue in Antifibrotic Drug in 2023
 Figure 19. Antifibrotic Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
 Figure 20. Global Antifibrotic Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Figure 21. North America Antifibrotic Drug Sales Market Share by Country (2019-2030)
 Figure 22. North America Antifibrotic Drug Revenue Market Share by Country (2019-2030)
 Figure 23. United States Antifibrotic Drug Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 24. Canada Antifibrotic Drug Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 25. Europe Antifibrotic Drug Sales Market Share by Country (2019-2030)
 Figure 26. Europe Antifibrotic Drug Revenue Market Share by Country (2019-2030)
 Figure 27. Germany Antifibrotic Drug Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 28. France Antifibrotic Drug Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 29. U.K. Antifibrotic Drug Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 30. Italy Antifibrotic Drug Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 31. Russia Antifibrotic Drug Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 32. Asia Pacific Antifibrotic Drug Sales Market Share by Region (2019-2030)
 Figure 33. Asia Pacific Antifibrotic Drug Revenue Market Share by Region (2019-2030)
 Figure 34. China Antifibrotic Drug Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 35. Japan Antifibrotic Drug Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 36. South Korea Antifibrotic Drug Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 37. India Antifibrotic Drug Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 38. Australia Antifibrotic Drug Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 39. China Taiwan Antifibrotic Drug Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 40. Southeast Asia Antifibrotic Drug Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 41. Latin America Antifibrotic Drug Sales Market Share by Country (2019-2030)
 Figure 42. Mexico Antifibrotic Drug Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 43. Brazil Antifibrotic Drug Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 44. Argentina Antifibrotic Drug Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 45. Colombia Antifibrotic Drug Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 46. Middle East and Africa Antifibrotic Drug Sales Market Share by Country (2019-2030)
 Figure 47. Middle East and Africa Antifibrotic Drug Revenue Market Share by Country (2019-2030)
 Figure 48. Turkey Antifibrotic Drug Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 49. Saudi Arabia Antifibrotic Drug Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 50. UAE Antifibrotic Drug Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 51. Global Sales Market Share of Antifibrotic Drug by Type (2019-2030)
 Figure 52. Global Revenue Market Share of Antifibrotic Drug by Type (2019-2030)
 Figure 53. Global Antifibrotic Drug Price (US$/Unit) by Type (2019-2030)
 Figure 54. Global Sales Market Share of Antifibrotic Drug by Application (2019-2030)
 Figure 55. Global Revenue Market Share of Antifibrotic Drug by Application (2019-2030)
 Figure 56. Global Antifibrotic Drug Price (US$/Unit) by Application (2019-2030)
 Figure 57. Antifibrotic Drug Value Chain
 Figure 58. Antifibrotic Drug Production Process
 Figure 59. Channels of Distribution (Direct Vs Distribution)
 Figure 60. Bottom-up and Top-down Approaches for This Report
 Figure 61. Data Triangulation
 Figure 62. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Nano String

SIMILAR REPORTS